ABSTRACT
Objective To study the phase Ⅱ clinical efficacy of paclitaxel and cisplatin combined with concurrent radiotherapy in the treatment of locally advanced esophageal squamous cell carcinoma.Methods Sixty-three cases of locally advanced esophageal squamous cell carcinoma patients were selected from January 2014 to January 2016 in our hospital.All patients were randomly divided into the study group (32 cases) and control group (31 cases) according to random number table method.All patients were treated with three-dimensional conformal radiotherapy,the control group was treated with 5-fluorouracil and cisplatin,and study group was treated with paclitaxel combined with cisplatin,21 days for a course of treatment,continuous 2 cycles of chemotherapy.The therapeutic effects and adverse reactions of the two groups of patients were evaluated.The levels of tumor markers such as carcino embryonic antigen (CEA),CA125 and CA50 were detected in the two groups before and after chemotherapy.The patients were followed up,and the survival rates were recorded.Results The effective rate of the patients in the study group was 93.75％,higher than that of the control group (74.19％,x2 =4.510,P =0.034).Compared with the control group,the radiation esophagitis (Z =2.076,P =0.038),neurotoxicity (Z =3.806,P ＜ 0.001),gastrointestinal reactions (Z =2.374,P =0.018),leukopenia (Z =1.979,P =0.048) were significantly lighter in the study group.After chemotherapy,the levels of CEA,CA125,CA50 of study group and control group were significantly lower than those before chemotherapy (all P ＜ 0.05),and the levels of study group after chemotherapy were significantly lower than those of the control group (all P ＜ 0.05).The 1-year survival rate of the patients in the study group was 90.63％,which was significantly higher than that in the control group (70.97％),and the difference was statistically significant (x2 =4.287,P =0.038).Conclusion Paclitaxel and cisplatin combined with concurrent radiotherapy can improve the phase Ⅱ therapeutic effect of locally advanced esophageal squamous cell carcinoma,the toxicity of chemotherapy in patients is low,effectively improve the short-term survival rate,with better clinical value.